AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China
AffaMed Therapeutics, a global clinical stage biopharmaceutical company dedicated to address critical unmet medical needs in neurological, psychiatric and ophthalmic disorders announced…
Read More...
Read More...
